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1  | INTRODUC TION
The global consumption of drugs to treat acute and chronic diseases 
continues to increase (WHO, 2011). Inevitably, healthcare profession‐
als are frequently confronted with patients using one or more drugs on 
a daily basis. These drugs can cause adverse effects in the oral region 
such as xerostomia, hyposalivation, mucositis, and taste disorders.
Due to the large number of different drugs available and their 
wide range of adverse effects, it is difficult and time‐consum‐
ing for healthcare professionals to take all the potential conse‐
quences into account during their daily practice. To support oral 
healthcare professionals in their decision making, the journal 
of Oral Diseases will publish a series of articles discussing the 
most frequent adverse effects of drugs in the oral region. The 
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Objective: Oral healthcare professionals are frequently confronted with patients 
using drugs on a daily basis. These drugs can cause taste disorders as adverse effect. 
The literature that discusses drug‐induced taste disorders is fragmented. This article 
aims to support oral healthcare professionals in their decision making whether a taste 
disorder can be due to use of drugs by providing a comprehensive overview of drugs 
with taste disorders as an adverse effect.
Materials and methods: The national drug information database for Dutch pharma‐
cists, based on scientific drug information, guidelines, and summaries of product 




with	 “dysgeusia”	 and	 61	 (3.7%)	 with	 “hypogeusia.”	 Drug‐induced	 taste	 disorders	
are reported in all drug categories, but predominantly in “antineoplastic and immu‐
nomodulating agents,” “antiinfectives for systemic use,” and “nervous system.” In 
~45%,	“dry	mouth”	coincided	as	adverse	effect	with	taste	disorders.
Conclusion: Healthcare professionals are frequently confronted with drugs reported 
to cause taste disorders. This article provides an overview of these drugs to sup‐
port clinicians in their awareness, diagnosis, and treatment of drug‐induced taste 
disorders.
K E Y W O R D S
drug‐induced taste disorders, drugs adverse effects, dysgeusia, hypogeusia, oral adverse 
effects
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution‐NonCommercial‐NoDerivs	License,	which	permits	use	and	distribution	in	
any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
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first paper in this series discusses drug‐induced taste disorders 
(DITD).
Fark,	 Hummel,	 Hahner,	 Nin,	 and	 Hummel	 (2013)	 divided	 taste	
disorders into quantitative taste disorders and qualitative taste disor‐
ders. Quantitative taste disorders include hypergeusia (an abnormally 
heightened sense of taste), normogeusia (a normal sense of taste), 
hypogeusia (an abnormally lowered sense of taste), and ageusia (a 
lacking sense of taste). Qualitative taste disorders are dysgeusia (a 
distortion in sense taste) and phantogeusia (a taste perception with‐
out	a	stimulus)	(Fark	et	al.,	2013).	Although	disturbances	in	taste	seem	
harmless, they can interfere with a patients’ social behavior by avoid‐
ing dinners or lead to a change in diet which can, among others, cause 
weight loss, nutrient deficiencies, or overweight due to excessive use 
of	salt	and	sugar	to	compensate	bad	flavors	(Noel,	Sugrue,	&	Dando,	
2017).	As	such,	taste	disorders	can	lead	to	a	significant	reduction	in	
the	quality	of	 life	 (Ponticelli	et	al.,	2017).	Therefore,	 it	 is	 important	




professionals in their decision making whether a taste disorder can be 
due to use of drugs by providing a comprehensive overview of drugs 
documented with taste disorders as an adverse effect.
2  | MATERIAL S AND METHODS
2.1 | Data source
The Informatorium Medicamentorum (IM) of the Royal Dutch 
Pharmacists	Association	(KNMP)	is	the	leading	national	drug	informa‐
tion	database	and	reference	work	for	pharmacists	in	the	Netherlands.	
This database is based on scientific drug information, guidelines, and 
summaries	 of	 product	 characteristics	 (SmPCs)	 (KNMP,	 2019).	 The	





ing adverse effects available that time were included in this study. Of 
each drug, the category “side effects” from the IM was searched for 
taste disorders and synonyms (e.g., dysgeusia).
The following characteristics of drugs causing DITD were regis‐
tered: generic name of the drug, term of the adverse effect, incidence 
of	 the	 adverse	 effect,	 and	 Anatomic	 Therapeutical	 Chemical	 (ATC)	
codes	of	the	drug.	The	ATC	classification	was	developed	by	the	World	
Health Organization and categorizes all active substances in drugs ac‐
cording to a hierarchy with five levels. It serves as a tool for exchanging 
data on drug use on a national and international level (WHO, 2003). 
It is worth noting that one active substance can be used in different 
drugs with different treatment goals. Therefore, it is possible that one 
active	substance	(e.g.,	miconazole)	has	several	ATC	codes	(Figure	1).
Originally, the terms used to describe one adverse effect (e.g., 
taste	disorders)	in	the	SmPCs	varied	between	drugs	and	through‐
out the years. In order to create a standardized structured data‐
base,	 the	MedDRA	classification	was	manually	 applied	 after	 the	
selection	 of	 drugs	 causing	 DITD.	 The	 MedDRA	 classification	 is	
developed by the International Council for Harmonization of 
Technical Requirements for Pharmaceuticals for Human and en‐
deavors to standardize all international medical terminology, in‐
cluding	 terms	 for	 adverse	effects	 (Meddra,	2019).	The	MedDRA	
classification is a hierarchical system that distinguishes five levels 
in the categorization of medical terminology. The most specific 
level	is	the	“Lowest	Level	Term	(LLT)”	and	the	next	level	is	called	
the	“Preferred	Term	(PT).”	Each	LLT	is	directly	linked	to	only	one	
PT.	 Each	 PT	 is	 linked	 to	 at	 least	 one	 LLT	 (itself)	 and	 sometimes	
several	synonyms	of	the	LLT.	 In	Figure	2,	the	PT	“Hypogeusia”	 is	
presented	 with	 its	 LLTs.	 After	 the	 selection	 of	 drugs	 related	 to	
DITD from the IM, the adverse effect terms were first matched 
F I G U R E  1  Hierarchy	of	ATC	levels	for	
miconazole [Colour figure can be viewed 
at wileyonlinelibrary.com]
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in	 accordance	with	 the	 support	 document	 (Meddra,	 2018),	with	
the	most	applicable	LLT	in	Dutch.	Terms	were	then	translated	into	
English	by	using	the	LLT	codes	and	the	English	version	of	MedDRA.	
The	 English	 LLT	was	 automatically	matched	with	 the	 English	 PT	
level	according	to	the	MedDRA	hierarchy.
Microsoft® Excel (version 16.16.1) was used to create the data‐
base with the acquired information on DITD and to perform descrip‐
tive statistics.
3  | RESULTS
In	 total,	 1,645	drugs	 (active	 substances)	were	 registered	 in	 the	 IM.	
Each drug can cause multiple adverse effects resulting in approxi‐
mately 65,000 unique combinations between a drug and an adverse 
effect	 in	 the	 IM.	Of	these	65,000	combinations,	2,335	 (3.5%)	were	





which can be administered rectally, nasally, and by inhalation, is reg‐
istered three times with dysgeusia as a potential adverse effect with 
three	different	incidences.	Table	1	presents	the	different	LLTs	and	PTs	
used in the IM for taste disorders and the number drugs which can 
potentially cause them. Taste disturbance as an adverse effect was 
reported	in	all	level	1	categories	of	the	ATC	classification	(Table	2).
“Normogeusia,”	 “hypergeusia,”	 “ageusia,”	 and	 “phantogeusia”	
were not reported in the IM.
3.1 | Dysgeusia
Dysgeusia	(PT)	as	an	adverse	effect	was	reported	282	times	(17.1%	
of	 1,645	 drugs)	 (Table	 1).	 The	 drug	 categories	 “antineoplastic	 and	
immunomodulating	agents”	(18.8%),	“antiinfectives	for	systemic	use”	
(15.6%),	and	“nervous	system”	(13.8%)	account	for	almost	half	of	the	
drug‐induced dysgeusia (Table 2). Hypergeusia, ageusia, and phanto‐
geusia were not reported.
Table 3 presents a selection of the drugs that could cause dysgeu‐
sia	(PT)	and	comprises	only	the	category	“Alimentary	tract	and	me‐
tabolism.” The frequencies of the adverse effect and whether a drug 
also causes the adverse effects “parosmia,” “anosmia,” “dry mouth,” 
or “hyposalivation” are presented as well, since these adverse effects 
are closely related to taste disorders. In some drugs, dysgeusia is only 





or	very	rare”	 in	9.9%	of	the	drugs.	 In	19.1%	of	the	drugs,	 the	“fre‐
quency was not known,” which means that in the IM, the frequency 
could not be estimated based on the available data.
Dysgeusia	coincided	in	114/282	drugs	(40.4%)	with	“dry	mouth”	
as	an	adverse	effect,	in	5/282	drugs	(1.7%)	with	“anosmia,”	in	2/282	
F I G U R E  2   Hierarchy of “Hypogeusia” 
in	MedDRA	[Colour	figure	can	be	viewed	
at wileyonlinelibrary.com]
TA B L E  1  LLTs	and	PT	for	taste	disorders	in	IM	analysis




















Hypogeusia was predominantly reported in the drug catego‐




reported to cause hypogeusia. In these 61 drugs, the frequency of 








been reported to potentially cause DITD (dysgeusia and hypogeusia). 
DITD	was	reported	in	all	ATC	level	1	categories,	suggesting	that	all	
healthcare professionals may frequently encounter the adverse ef‐
fects of these drugs. Healthcare professionals that treat patients 
using antineoplastic drugs are most likely to be confronted with 
DITD. Despite the recorded percentage of our search, the exact inci‐
dence of DITD is unclear due to a lack of systematic well controlled 
clinical	trials	(Schiffman,	2018).
To the best of our knowledge, this study is the first compre‐
hensive overview of DITD based on the analysis of a national drug 
information database which includes adverse effects. The available 
literature that discusses DITD is fragmented, since previous articles 
usually report on a specific type of patients with DITD (e.g., cancer) 
(de	Coo	&	Haan,	2016;	Okada	et	al.,	2016;	Tuccori	et	al.,	2011),	spe‐
cific drug categories causing DITD (e.g., cardiovascular drugs) (Che, 
Li,	Fang,	Reis,	&	Wang,	2018;	van	der	Werf,	Rovithi,	Langius,	de	van	
der	Schueren,	&	Verheul,	2017)	or	summarize	the	literature	instead	








be underreported compared to previous studies which do not use the 
MedDRA.	It	also	has	to	be	mentioned	that	the	terms	and	incidences	
used in the database (e.g., "dysgeusia", "hypoguesia") are based on 
patient‐reported adverse effects during pharmacological developing 
studies or postmarketing studies. This subjective reporting by patients 
ATC level 1 category Dysgeusia (%) Hypogeusia (%) Total
Alimentary	tract	and	
metabolism
24	(8.5) 2 (3.1) 26
Antiinfectives	for	systemic	use 44(15.6) 7	(11.0) 51
Antineoplastic	and	immunomod‐
ulating agents




Blood	and	blood	forming	organs 13	(4.6) 1	(1.4) 14
Cardiovascular system 23	(8.1) 5	(7.8) 28
Dermatologicals 13	(4.6) 2 (3.2) 15
Genitourinary system and sex 
hormones
5	(1.7) 3	(4.7) 8
Musculoskeletal system 12	(4.3) 2 (3.1) 14
Nervous	system 39	(13.8) 12 (19.0) 51
Respiratory system 16	(5.7) ‐ 16
Sensory	organs 10 (3.5) 1 (1.5) 10
Systemic	hormonal	prepara‐
tions, excl.
7	(2.5) 2 (3.1) 9
Various 18	(6.3) 2 (3.1) 20
Total 282 61 343
TA B L E  2  Number	of	drugs	causing	
dysgeusia	or	hypogeusia	per	ATC	level	1	
category
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might lead to a reporting bias or inaccuracy in terminology. The differ‐
ence between objective and subjective adverse effects measuring is 
a common point of discussion when reporting on adverse effects and 
one without a clear solution. When considering taste disorders, there 
is no commonly used test available for objectifying taste disorders, 
which makes it impossible to report solely objective data. In order to 
make future studies on oral adverse effects more comparable, it is 
recommended	 that	 the	MedDRA	 terminology	 and	hierarchy	 and,	 if	
available, objective tests are used during data collection and describ‐
ing the results. Homogenous reporting of results, on for instance inci‐
dences, will lead to clinically more applicable data.
Due to differences in local and regional laws and regulations on 
drug admission, registered drugs differ per country. Thus, there will 
be drugs that are reported in the current study that are not avail‐
able in some countries and reverse. However, with regard to the 
European countries, most of the reported drugs will be available in 
all	countries.	By	applying	the	ATC	and	MedDRA	classification,	 the	
data are internationally applicable and could serve as a guidance for 
future reports on DITD.
The exact mechanisms underlying DITD are still unclear and may 
vary between individuals. Individual variations may be caused by poly‐




metallic taste. These drugs interact with the taste buds: (a) after oral 
application, (b) by diffusion into the saliva after absorption in the gut 
or intravenous administration, or (c) by accumulation in the taste buds 
when used chronically. The latter might explain why DITD can occur 
months or years after the initial usage (e.g., lithium carbonate). Other 
drugs distort taste and smell signals for sweet or salt, causing a bitter 
or sour taste perception of food and beverages. The garlic‐like taste 
caused by disulfiram is due to exhalation of carbon disulfide. Drug–
drug interactions can lead to elevated blood plasma levels beyond 
therapeutic concentrations and therefore cause DITD, which particu‐
larly could occur in polypharmacy patients.
Saliva	could	also	play	a	role	in	the	underlying	mechanism	of	DITD.	
Saliva	 protects	 the	 external	 environment	 of	 the	 taste	 receptor	 cells	
and acts as a solvent and transportation medium for taste substances 
(Matsuo, 2000). Many drugs are known to cause quantitative or 
qualitative	changes	 in	 saliva	 (Wolff	et	 al.,	2017).	Almost	45%	of	 the	
drugs known to potentially cause DITD coincided with dry mouth 
as an adverse effect, suggesting that there is at least some correla‐
tion. However, the exact correlation is difficult to assess since both 
MedDRA	and	the	data	that	underlie	the	IM	do	not	clearly	discriminate	
between subjective “xerostomia” and objective “hyposalivation.” The 
term “dry mouth” is presumably used for both.
A	healthcare	professional	confronted	with	a	patient	with	DITD	
should assess which drug, or drug combination, is presumably re‐
sponsible for the DITD. This can be done by comparing the tem‐
poral onset of DITD with the alterations in the drug usage (e.g., 
dosage, new drugs). However, as stated before, it is possible that 





































































































































































































































































































































































































































































































222  |     RADEMACHER Et Al.
the	assessment	of	a	temporal	relationship.	Another	possibility	is	to	
consult pharmaceutical databases and overviews like the approach 
used in the present study.
Cessation of the drug responsible for DITD will most likely result 
in a decrease and eventually even recovery of DITD, but this (par‐
tial) recovery could take months. If cessation and alterations are not 
possible, other treatment modalities could be considered to relieve 
the symptoms. The evidence behind these modalities is scarce and 
based on research on taste disorders with other causes than DITD. 
Proposed treatment modalities include improving oral hygiene, 




Healthcare professionals are frequently confronted with drugs that 
are documented with DITD. The exact incidences of DITD remain 
unclear. This overview supports clinicians in their awareness, diag‐
nosis, and possible treatment of DITD, and could serve as a refer‐
ence for future research reporting on DITD.
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